Dow Dips Over 200 Points; McDonald's Tops Q2 Expectations
Portfolio Pulse from Lisa Levin
US stocks fell on Thursday, with the Dow Jones dropping 0.59% and the NASDAQ falling 0.44%. McDonald's Corp (MCD) reported better-than-expected Q2 results, with sales growth of 13.6% YoY to $6.50 billion. Carmell Therapeutics Corporation (CTCX) shares rose 71% after announcing a merger with Axolotl Biologix. Femasys Inc. (FEMY) shares rose 128% after the US Patent and Trademark Office issued a Notice of Allowance for FemBloc. North American Construction Group Ltd. (NOA) shares rose 35% after better-than-expected Q2 results. Mersana Therapeutics, Inc. (MRSN) shares fell 78% after its UPLIFT clinical trial did not meet the primary endpoint. TPI Composites, Inc. (TPIC) shares fell 34% after lowering its 2023 forecast. Asensus Surgical, Inc. (ASXC) shares fell 39% after reporting a $10 million registered direct offering.
July 27, 2023 | 6:40 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Carmell Therapeutics announced a merger with Axolotl Biologix, leading to a 71% rise in shares.
Mergers often lead to a rise in stock price due to potential synergies and growth opportunities.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100
POSITIVE IMPACT
Femasys Inc. shares rose 128% after the US Patent and Trademark Office issued a Notice of Allowance for FemBloc.
Positive regulatory news often leads to a rise in stock price due to potential market opportunities.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100
POSITIVE IMPACT
McDonald's reported better-than-expected Q2 results, beating analyst consensus.
Positive earnings reports typically lead to a rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
North American Construction Group Ltd. shares rose 35% after better-than-expected Q2 results.
Positive earnings reports typically lead to a rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Asensus Surgical shares fell 39% after reporting a $10 million registered direct offering.
Direct offerings often lead to a fall in stock price due to potential dilution of existing shares.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100
NEGATIVE IMPACT
Mersana Therapeutics shares fell 78% after its UPLIFT clinical trial did not meet the primary endpoint.
Negative clinical trial results often lead to a fall in stock price due to potential loss of market opportunities.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100
NEGATIVE IMPACT
TPI Composites shares fell 34% after lowering its 2023 forecast.
Negative forecast revisions often lead to a fall in stock price due to potential future earnings risks.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100